Active	Status	Sponsor type	Region	Phase	Filter
4 Active 2 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
FERRARI, Carlo
D-LIVR, NCT03719313 / 2018-003167-54: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a	Completed	3	407	Europe, Canada, US, RoW	Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir	Eiger BioPharmaceuticals	Hepatitis Delta Virus	10/22	03/23
IP-CURE-B, NCT05045261: ANRS HB07 IP-Cure-B Proof of Concept (PoC) Clinical Trial. Educating the Liver Immune Environment Through TLR8 Stimulation Followed by NUC Discontinuation	Recruiting	2	100	Europe	administration of SLGN in arm C, Discontinuation of NUC treatment in arms B and C	ANRS, Emerging Infectious Diseases, EUCLID Clinical Trial Platform	Hepatitis B, Chronic	06/24	06/24
CirB-RNA, NCT03825458: Creation of a Cohort for the Quantitation and Characterization of Circulating Viral RNAs as a New Biomarker of Hepatitis B Functional Cure.	Recruiting	N/A	3500	Europe	Blood sampling	Hospices Civils de Lyon	Hepatitis B	06/29	06/29
HDV Describe, NCT05723068: Burden of Hepatitis D Virus (HDV) Infection in Italy	Completed	N/A	515	Europe		University of Turin, Italy, Gilead Sciences	Chronic Hepatitis D	06/24	12/24